Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myovant Sciences Ltd.

http://myovant.com/

Latest From Myovant Sciences Ltd.

Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant

Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications. 

Deals Approvals

Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint

The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.

Clinical Trials Cancer

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
  • Other Names / Subsidiaries
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
UsernamePublicRestriction

Register